Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapyHanna Schneider(Philipps University of Marburg), Eike Gallmeier(Universitätsklinikum Gießen und Marburg)NeoplasiaAugust 10, 202410.1016/j.neo.2024.101038Cited by 5SaveCiteExport RISWatch citationsRelated PapersA synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers|Oncotarget|2016|41